Background: The prevalence of hepatitis B surface antigen (HBsAg) and anti-HCV infection (anti-HCV) among hemodialysis patients (HD) varies from country to country and from one center to another. This cross-sectional study was conducted to investigate seroprevalence and associated risk factors for HBsAg and anti-HCV markers among hemodialysis patients in S.O. CHU in Lomé.
Materials and methods: Structured questionnaires were used to obtain socio-demographic data and sera were tested for HBsAg and anti-HCV among End Stage Renal Disease (ESRD) patients undergoing hemodialysis in S.O. CHU in Lomé. Results: Out of 75 patients enrolled in the study, HBsAg and anti-HCV were detected in 6 (8%) and 11 (14.7%) patients respectively. Anti-HCV and HBsAg seropositivity were not associated with the hemodialysis session (p = 0.88) and (p = 0.91) respectively. Furthermore, Univariate analysis showed that, sex, tatoo before dialysis and a history of surgery were not a significant risk factors for HBsAg and HCV seropositivity. The follow-up of the ALT in the both patients (HCV and HBsAg) showed very high significant variation (p = 0.000) and (p = 0.02) respectively. Conclusion: Prevalence of HBsAg and anti-HCV in hemodialysis patients seems low in Lomé. It is recommended to check the patients for HBsAg and anti-HCV before admission to the centers.

Seroepidemiology; HBV; HCV; hemodialysis; Togo